← Back to Screener
Kairos Pharma, Ltd. (KAPA)
Price$0.44
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-55.15%
Price vs S&P 500 (4W)-21.42%
VGM Score29.53
Market Capitalization$9.42M
All Metrics
Book Value / Share (Quarterly)$0.25
P/TBV (Annual)2.35x
Cash Flow / Share (Quarterly)$-0.18
Price vs S&P 500 (YTD)-46.19%
EPS (TTM)$-0.30
10-Day Avg Trading Volume0.12M
EPS Excl Extra (TTM)$-0.30
EPS (Annual)$-0.30
ROI (Annual)-85.90%
Cash / Share (Quarterly)$0.17
ROA (Last FY)-83.29%
EBITD / Share (TTM)$-0.29
Cash Flow / Share (Annual)$-0.17
P/B Ratio1.77x
P/B Ratio (Quarterly)2.25x
Net Income / Employee (Annual)$-5,447,000
Net Interest Coverage (TTM)-2.03x
ROA (TTM)-86.43%
EPS Incl Extra (Annual)$-0.30
Current Ratio (Annual)27.07x
Quick Ratio (Quarterly)9.98x
3-Month Avg Trading Volume0.40M
52-Week Price Return-12.44%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.25
52-Week High$2.11
EPS Excl Extra (Annual)$-0.30
26-Week Price Return-47.22%
Quick Ratio (Annual)26.81x
13-Week Price Return-32.93%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.31x
Enterprise Value$5.75M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.22
3-Month Return Std Dev58.57%
Net Income / Employee (TTM)$-5,839,000
ROE (Last FY)-85.90%
Net Interest Coverage (Annual)-2.01x
EPS Basic Excl Extra (Annual)$-0.30
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.30
ROI (TTM)-92.26%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.30
Price vs S&P 500 (52W)-36.80%
Year-to-Date Return-38.03%
5-Day Price Return-10.97%
EPS Normalized (Annual)$-0.30
ROA (5Y Avg)-138.86%
Month-to-Date Return-13.62%
EBITD / Share (Annual)$-0.29
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.30
P/TBV (Quarterly)2.26x
P/B Ratio (Annual)2.33x
Book Value / Share (Annual)$0.30
Price vs S&P 500 (13W)-41.18%
Beta1.62x
P/FCF (Annual)116.31x
Revenue / Share (TTM)$0.00
ROE (TTM)-92.26%
52-Week Low$0.43
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.08est. -0.08
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KAPAKairos Pharma, Ltd. | — | — | D | $0.44 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Kairos Pharma is a clinical-stage biopharmaceutical company developing cancer immunotherapies designed to overcome immune suppression and drug resistance. Its pipeline includes antibody and small molecule candidates targeting prostate cancer, lung cancer, breast cancer, and glioblastoma.